EPO issues intention to grant patent for Vistagen’s PH80 nasal spray

14 Jun 2023
www.pharmaceutical-technology.com
EPO issues intention to grant patent for Vistagen’s PH80 nasal spray
Preview
Source: Pharmaceutical Technology
Vistagen’s PH80 nasal spray will be used to treat migraines, including those associated with traumatic brain injury. Credit: Hermes Rivera on Unsplash.
The European Patent Office (EPO) has issued an intention to grant a patent for Vistagen’s new PH80 nasal spray to treat migraine.
The patent’s claims also include treatment given at the onset of migraine symptoms as well as the treatment of migraines associated with traumatic brain injury.
Recommended Reports
EPO issues intention to grant patent for Vistagen’s PH80 nasal spray
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - CKHT-5108 in AlopeciaAlopecia GlobalData
EPO issues intention to grant patent for Vistagen’s PH80 nasal spray
Preview
Source: Pharmaceutical Technology
ReportsLOA and PTSR Model - Minocycline Hydrochloride Er in Rosacea GlobalData
View all
The patent will remain active until at least 2040.
PH80 is a first-in-class, rapid-onset nasal spray designed to be used in a similar way to a rescue asthma inhaler.
It offers patient-tailored, user-friendly, intranasal administration as required, up to multiple times a day.
PH80 has a potential rapid-onset mechanism of action (MOA) which is fundamentally differentiated from all existing approved treatments for migraine.
The therapy’s MOA does not need systemic exposure or direct action on the neurons of the central nervous system (CNS) to create a therapeutic effect.
This is a significant potential treatment advantage over traditional pharmaceuticals, including existing migraine treatments.
The new nasal spray works by initiating neural impulses in the olfactory bulb that quickly affect the functioning of multiple structures in the brain connected to migraine pathology, including the amygdala and hypothalamus.
In March 2023, PH80 nasal spray received a patent from the US Patent and Trademark Office (USPTO) to treat migraine.
Vistagen stated that the PH80 development programme focuses on the acute treatment of migraine and also on the management of menopausal hot flushes.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.